Flag of the European Union EU Clinical Trials Register Help

Clinical trials for GP5

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: GP5. Displaying page 1 of 1.
    EudraCT Number: 2018-000452-18 Sponsor Protocol Number: ETB115J2411 Start Date*: 2018-09-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (...
    Medical condition: immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    22.1 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GR (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001088-29 Sponsor Protocol Number: CJDQ443B12201 Start Date*: 2022-10-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-sm...
    Medical condition: locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) BE (Trial now transitioned) BG (Completed) NL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003024-16 Sponsor Protocol Number: ACT16482 Start Date*: 2021-06-30
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol
    Medical condition: Plasma cell myeloma refractory
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081847 Plasma cell myeloma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FR (Completed) GR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000366-11 Sponsor Protocol Number: ENGOT-Ov41/GEICO69-O/ANITA Start Date*: 2018-10-31
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO)
    Full Title: A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ov...
    Medical condition: Recurrent ovarian, tubal or peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Restarted) FR (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000241-14 Sponsor Protocol Number: ADCT-402-311 Start Date*: 2021-01-26
    Sponsor Name:ADC Therapeutics SA
    Full Title: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000367-83 Sponsor Protocol Number: ENGOT-Cx10/GEICO68-C/BEATcc Start Date*: 2018-08-08
    Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO)
    Full Title: A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persi...
    Medical condition: Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008342 Cervix carcinoma PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003126-25 Sponsor Protocol Number: DZ2019E0001 Start Date*: 2022-02-14
    Sponsor Name:Dizal (Jiangsu) Pharmaceutical Co., Ltd
    Full Title: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001072-37 Sponsor Protocol Number: IRFMN-EN-7556 Start Date*: 2019-01-29
    Sponsor Name:IRCCS - Istituto di Ricerche Farmacologiche Mario Negri
    Full Title: AtTEnd: Atezolizumab Trial in Endometrial cancer - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/r...
    Medical condition: Newly diagnosed, histologically-confirmed stage III-IV endometrial carcinoma/carcinosarcoma with residual disease after surgery, either measurable or evaluable, and naïve to first line systemic ant...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10014772 Endometrioid adenocarcinoma recurrent LLT
    21.1 100000004864 10014776 Endometrioid adenocarcinoma stage III LLT
    21.1 100000004864 10014777 Endometrioid adenocarcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001400-41 Sponsor Protocol Number: BNT113-01 Start Date*: 2021-01-06
    Sponsor Name:BioNTech SE
    Full Title: An open-label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic H...
    Medical condition: Unresectable recurrent, or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) which is positive for human papilloma virus 16 (HPV16+) and expresses PD-L1
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 01:26:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA